2017 Annual Meeting
SC08-The Pathologists Role in Guiding Breast Cancer Treatment in the Era of Neoadjuvant Therapy
March 8 2017, 8:00am to 12:00pm
SC08-The Pathologist's Role in Guiding Breast Cancer Treatment in the Era of Neoadjuvant Therapy
Session Credits: 3 CME and 3 SAMs
Faculty: W. Fraser Symmans, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Veerle Bossuyt, MD Yale University, New Haven, CT and Elena Provenzano, MD Addenbrookes Hospital, Cambridge, UK
The increasing use of neoadjuvant treatment for advanced and early stage breast cancer has introduced new challenges in the handling and reporting of breast specimens in this clinical context. This practical short course will provide a forum to review and discuss current evidence, and enable general pathologists, pathologists with special expertise in breast pathology, residents, fellows and physician assistants to develop practical approaches for specific scenarios that can be incorporated in routine practice. A combination of short didactic lectures and case studies will set the stage for an interactive discussion. Each participant will have the opportunity to ask questions about specific scenarios posing a dilemma in routine practice. Topics covered will include complete pathologic response, grading of partial response, response in the lymph nodes, evaluation of the axilla before and after treatment, practical approach to sampling of the post- neoadjuvant surgical specimen, detailed method for calculating the residual cancer burden (RCB) score, controversial scenarios and minimum dataset to be reported by the pathologist. Virtual slides, still images and histories illustrating various scenarios and a syllabus including PowerPoint presentations and references will be provided online before the meeting. Pre-registrants will be polled before the course with a questionnaire regarding common areas of difficulty or controversy and given the opportunity to submit questions in advance. A post-test will also be available. All course registrants will receive access to the PowerPoint slides presented at the USCAP Annual Meeting.
Upon completion of this educational activity, participants should be able to:
- Recognize and consider the role of pathology reporting in neoadjuvant clinical trials and treatment decisions for individual patients after neoadjuvant therapy
- Evaluate different pathologic prognostic factors after neoadjuvant therapy
- Develop a practical approach to the pathologic evaluation of breast specimens following neoadjuvant treatment including gross description, sampling, microscopic evaluation and reporting based on the evidence presented.